Interview: Ellson Chen, President & CEO, Vita Genomics, Taiwan
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
Address: 7 Fl., No. 6, Sec. 1, Jung-Shing Road, Wugu Shiang, Taipei, Taiwan
Tel: (+886) 2-8976-9123
Web: http://www.vitagenomics.com/
Vita Genomics, founded in March 2001, has established its headquarter in Taiwan, a marketing office in California, USA, and a wholly owned subsidiary GeneCore in Shanghai, China. Vita Genomics has envisioned itself to be an important player in the healthcare industry by offering advanced and targeted molecular diagnostic products and services, providing more efficient and safer medical solutions, improving the drug development process, and lowering the overall healthcare cost through the pharmacogenomics approaches.Vita Genomics has already built up strong relationships with research institutions and medical organizations throughout Taiwan and China. We are constantly looking for pharmaceutical partners who can benefit from identifying patients for drug responsiveness prior to treatments, partners who would fund expanded pharmacogenomics studies that will enable us to validate the responsiveness of all significant genotypes, and partners who would co-develop DNA-based molecular diagnostic products. Vita Genomics is an active participant in modernizing Taiwan healthcare system. We are establishing the infrastructure needed to add the molecular profile information to the healthcare integrated circuit (IC) card. This is a first step in creating personalized medicine in the future. In addition, Vita Genomics can act as the conduit between the western world and China because we have already established a beachhead in Shanghai.
Vita Genomics follows the high standards of US FDA guidelines in collecting samples in conducting research and clinical studies.Vita Genomics concentrates on the elucidation of the genes and pathways involved in various diseases and on the drug responsiveness of patients in an attempt to improve the healthcare system.
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
Francis Hong, chairman of Taiwan Medical and Biotech Industry Association (TMBIA), takes a moment during the 2019 Medical Taiwan and Taiwan Medical Components & Manufacturing Expo (MCMEX) in Taipei to share…
Mengchu Wu, CEO of Health Genetech, introduces the innovative precision medicine company as it prepares to transition from a research-positioned provider to a healthcare partner. Wu goes on to offer…
Today Su, CEO of Golden Biotechnology, introduces the innovative biotech developing a revolutionary botanical drug derived from the Taiwanese fungus Antrodia Camphorata. The company’s drug, Hocena®, has already received several…
Barry Lam, founder and chairman of Quanta Computer, shares the story of how he built the company into one of the world’s leading electronics and IT manufacturers. Lam then sheds…
With the USA and China locked in a trade war, China’s near neighbour Taiwan – with its strong scientific and technology base, political security and economic reliability – may stand…
Professor Shih-Hua Lin, president of Taiwan’s National Defense Medical Center, shares an overview of the academic and research environment of the institute as well as its role in cultivating the…
Scott Li, deputy director of H Spectrum, a biotech and talent incubator within the Foxconn group, explains the organization’s history and unique role in supporting Foxconn’s transition into healthcare. Li…
William Foreman, president of AmCham Taipei, describes the attractiveness and challenges of Taiwan’s business landscape and the implications of US-China relations on the island. Foreman goes on to highlight the…
Leo Liu, president of GeneReach Biotechnology Corp, shares the story of the diagnostics startup and explains his strategy to transition the company from a leading animal health point-of-care device manufacturer…
Susan Hsu, managing director of Taiwanese data-driven CRO StatPlus, speaks about the key trends impacting Taiwan’s clinical trial environment and goes on to share her views on the increasing attractiveness…
Tony Chung, CEO of Instant NanoBiosensors explains the potential of their fibre-optic biosensor technology – FOPPR, and the commercialization strategy for their light-sensing biomarker analyzer INB-D200. He also highlights Taiwan’s…
Shing-Mou Lee, founder and president of EMO Biomedicine, the leading CDMO provider of cell-based products in Taiwan, discusses the major regulatory and maturation trends in the region and shares his…
See our Cookie Privacy Policy Here